Abcam was established in 1998 by Jonathan Milner, David Cleevely and Tony Kouzarides in Cambridge, UK. Their mission was to source and sell online the best research antibodies in the world, together with the most comprehensive data, fast delivery, helpful customer service and technical support.
Today, with over 20 years of experiences, facilities in Europe, USA and Asia and customers in over 130 countries, we are a leading global proteomics pioneer that identifies, develops, and manufactures quality biological, protein, and custom cell engineering tools to the life science research and clinical communities.
(£217.1m for FY2016/17)
Adding multiplex and MiRNA assay capabilities
Proving in vitro recombinant monoclonal antibody capabilities (phage display)
(£122.2m for FY2012/13)
Enhancing Abcam’s offering in high-performance biochemicals
Bringing immunoassay capabilities in-house